SANTEN PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,512 JPY | +1.41% |
|
+4.13% | +7.65% |
| Sales 2024 * | 301B 1.93B | Sales 2025 * | 292B 1.87B | Capitalization | 543B 3.47B |
|---|---|---|---|---|---|
| Net income 2024 * | 31.72B 203M | Net income 2025 * | 33.23B 212M | EV / Sales 2024 * | 1.83 x |
| Net Debt 2024 * | 10.05B 64.19M | Net cash position 2025 * | 14.69B 93.83M | EV / Sales 2025 * | 1.81 x |
| P/E ratio 2024 * |
16.4
x | P/E ratio 2025 * |
16.2
x | Employees | 4,144 |
| Yield 2024 * |
2.2% | Yield 2025 * |
2.24% | Free-Float | 93.7% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.41% | ||
| 1 week | +4.13% | ||
| Current month | -1.56% | ||
| 1 month | +1.71% | ||
| 3 months | +2.79% | ||
| 6 months | +17.70% | ||
| Current year | +7.65% |
1 week
1 460.00
1 527.50
1 month
1 394.501 548.00
Current year
1 394.501 589.50
1 year
1 075.001 589.50
3 years
956.001 718.00
5 years
956.002 234.00
10 years
900.002 234.00
| Managers | Title | Age | Since |
|---|---|---|---|
Takeshi Ito
CEO | Chief Executive Officer | 64 | 82-03-31 |
Kazuo Koshiji
DFI | Director of Finance/CFO | - | - |
Akira Kurokawa
CHM | Chairman | 71 | 77-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Akira Kurokawa
CHM | Chairman | 71 | 77-03-31 |
Kanoko Oishi
BRD | Director/Board Member | 63 | 15-05-31 |
Noboru Kotani
BRD | Director/Board Member | 67 | 22-06-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.22% | 15 M€ | +7.34% | ||
| 0.19% | 1,120 M€ | -0.07% | ||
| 0.13% | 81 M€ | +14.05% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1,512 | +1.41% | 2 723 000 |
| 24-04-25 | 1,492 | -0.90% | 1,366,700 |
| 24-04-24 | 1,505 | -0.20% | 2,396,700 |
| 24-04-23 | 1,508 | +2.52% | 2,191,700 |
| 24-04-22 | 1,471 | +1.27% | 1,024,000 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1,492
JPY
Average target price
1,767
JPY
Spread / Average Target
+18.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.65% | 3.49B | |
| +24.85% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.14% | 233B | |
| +5.53% | 201B | |
| -9.98% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 4536 Stock
